Stockscreener 앱 받기
39.21
4.69%
-1.93
시간 외 거래:
39.39
0.18
+0.46%
전일 마감가:
$41.14
열려 있는:
$41.46
하루 거래량:
304.23K
Relative Volume:
1.00
시가총액:
$1.75B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-10.27%
1개월 성능:
+0.51%
6개월 성능:
+87.88%
1년 성능:
+0.00%
1일 변동 폭
$38.93
$41.56
1주일 범위
$38.93
$45.00
52주 변동 폭
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
명칭
Sionna Therapeutics Inc
전화
617-819-2020
주소
21 HICKORY DRIVE, SUITE 500, WALTHAM
SION을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
39.21 | 1.84B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-04 | 개시 | Guggenheim | Buy |
| 2025-03-04 | 개시 | Stifel | Buy |
| 2025-03-04 | 개시 | TD Cowen | Buy |
모두보기
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
Sionna Therapeutics Insider Sold Shares Worth $1,486,010, According to a Recent SEC Filing - marketscreener.com
Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 33,356 Shares - Defense World
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 33,356 Shares of Stock - MarketBeat
OrbiMed Advisors sells Sionna Therapeutics [SION] shares for $1.48m By Investing.com - Investing.com Nigeria
OrbiMed Advisors sells Sionna Therapeutics [SION] shares for $1.48m - Investing.com
Sionna Therapeutics (NASDAQ:SION) Sets New 12-Month HighWhat's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Broadens Clinical Research Scope - Kalkine Media
Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis - TipRanks
FY2025 Earnings Estimate for SION Issued By Lifesci Capital - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Sionna Therapeutics (SION) with Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage on Sionna Therapeutics With Outperform Rating, $60 Price Target - marketscreener.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $40,050.00 in Stock - Defense World
Sionna Therapeutics, Inc.(NasdaqGM:SION) added to S&P Biotechnology Select Industry Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) added to NASDAQ Biotechnology Index - marketscreener.com
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year High – Still a Buy? - Defense World
Peter Thompson Sells 900 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Director Sells $38,928.75 in Stock - MarketBeat
Shareholder OrbiMed Advisors LLC Sells 1,875 ($83.4K) Of Sionna Therapeutics Inc [SION] - TradingView — Track All Markets
Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year HighHere's What Happened - MarketBeat
How Sionna Therapeutics Inc. stock reacts to oil pricesTrade Entry Summary & Short-Term Trading Alerts - Улправда
Sionna Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Braidwell LP Invests $18.77 Million in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat
Sionna Therapeutics (SION) Stock Analysis Report | Financials & Insights - Benzinga
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sionna Therapeutics chief legal officer sells $415,330 in stock By Investing.com - Investing.com Canada
Sionna Therapeutics chief legal officer sells $415,330 in stock - Investing.com India
Sionna Therapeutics Insider Sold Shares Worth $415,330, According to a Recent SEC Filing - marketscreener.com
Officer Fitzpatrick Sells 10,250 ($415.3K) Of Sionna Therapeutics Inc [SION] - TradingView — Track All Markets
Bosun Asset Management LLC Invests $295,000 in Sionna Therapeutics, Inc. $SION - Defense World
Officer Fitzpatrick Files To Sell 10,250 Of Sionna Therapeutics Inc [SION] - TradingView
Sionna Therapeutics, Inc. $SION Shares Acquired by Prudential Financial Inc. - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Up 11.4%What's Next? - MarketBeat
Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says - marketscreener.com
Transcript : Sionna Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09 - marketscreener.com
Why Sionna Therapeutics Inc. stock remains resilient2025 Short Interest & Long-Term Growth Portfolio Plans - Newser
Will Sionna Therapeutics Inc. stock gain from government policies - Newser
Sionna Therapeutics, Inc. $SION Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownHere's What Happened - MarketBeat
Views of Wall Street’s Leading Experts on Sionna Therapeutics Inc - Setenews
Royal Bank Of Canada Reiterates "Underperform" Rating for Sionna Therapeutics (NASDAQ:SION) - MarketBeat
Is Sionna Therapeutics Inc. stock affected by interest rate hikesGold Moves & Precise Entry and Exit Recommendations - Newser
Sionna Therapeutics Shares Lower After RBC Downgrade - marketscreener.com
Sionna Therapeutics stock tumbles after RBC downgrade By Investing.com - Investing.com Canada
SION Downgraded by RBC Capital: Today's Analyst Rating | SION St - GuruFocus
Sionna Therapeutics Inc (SION) 재무 분석
Sionna Therapeutics Inc (SION)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):